CORRECTION article

Front. Oncol., 14 December 2021

Sec. Gastrointestinal Cancers: Hepato Pancreatic Biliary Cancers

Volume 11 - 2021 | https://doi.org/10.3389/fonc.2021.823960

Corrigendum: Real-World Lenvatinib Versus Sorafenib in Patients With Advanced Hepatocellular Carcinoma: A Propensity Score Matching Analysis

This article is a correction to:

  1. Real-World Lenvatinib Versus Sorafenib in Patients With Advanced Hepatocellular Carcinoma: A Propensity Score Matching Analysis

    1. Read original article
Yuan-Hung KuoYuan-Hung Kuo1Sheng-Nan LuSheng-Nan Lu1Yen-Yang ChenYen-Yang Chen2Kwong-Ming KeeKwong-Ming Kee1Yi-Hao YenYi-Hao Yen1Chao-Hung HungChao-Hung Hung1Tsung-Hui HuTsung-Hui Hu1Chien-Hung ChenChien-Hung Chen1Jing-Houng Wang*Jing-Houng Wang1*
  • 1Division of Hepatogastroenterology, Department of Internal Medicine, Kaohsiung Chang Gung Memorial Hospital and Chang Gung University College of Medicine, Kaohsiung, Taiwan
  • 2Division of Hematology-Oncology, Department of Internal Medicine, Kaohsiung Chang Gung Memorial Hospital and Chang Gung University College of Medicine, Kaohsiung, Taiwan

A Corrigendum on
Real-World Lenvatinib Versus Sorafenib in Patients With Advanced Hepatocellular Carcinoma: A Propensity Score Matching Analysis

By Kuo Y-H, Lu S-N, Chen Y-Y, Kee K-M, Yen Y-H, Hung C-H, Hu T-H, Chen C-H and Wang J-H (2021) Front. Oncol. 11:737767. doi: 10.3389/fonc.2021.737767

In the original article, there was an error. The IRB Number of our article, “IRB No: 202100961B0”, was typed mistakenly as “IRB No: 20210096B0”.

A correction has been made to the last sentence of the Materials and Methods, Patients and the Ethics Statement”.

The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.

Publisher’s Note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Keywords: hepatocellular carcinoma, lenvatinib, propensity score (PS) matching (PSM), sorafenib, progression-free survival

Citation: Kuo Y-H, Lu S-N, Chen Y-Y, Kee K-M, Yen Y-H, Hung C-H, Hu T-H, Chen C-H and Wang J-H (2021) Corrigendum: Real-World Lenvatinib Versus Sorafenib in Patients With Advanced Hepatocellular Carcinoma: A Propensity Score Matching Analysis. Front. Oncol. 11:823960. doi: 10.3389/fonc.2021.823960

Received: 28 November 2021; Accepted: 01 December 2021;
Published: 14 December 2021.

Approved by:

Frontiers Editorial Office, Frontiers Media SA, Switzerland

Copyright © 2021 Kuo, Lu, Chen, Kee, Yen, Hung, Hu, Chen and Wang. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

*Correspondence: Jing-Houng Wang, amluZ2hvdW5nMjAwMUB5YWhvby5jb20udHc=

Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.